Acutus Medical, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021
January 19, 2022 at 06:00 am EST
Share
Acutus Medical, Inc. provided preliminary earnings guidance for the fourth quarter and full year ended December 31, 2021. For the quarter, the company expects fourth quarter 2021 revenues of approximately $4.2-4.4 million compared to $2.6 million in the fourth quarter of 2020.
Full year 2021 revenues are expected to be in a range of $17.1-17.3 million compared to $8.5 million for the full year 2020 and within the guidance range provided on the third quarter 2021 earnings call. Year-over-year growth in the fourth quarter and full year was driven by increased procedure volumes, new product adoption, and higher capital sales.
Acutus Medical, Inc. is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. (Medtronic). The Company is solely focused on supporting the manufacturing and distribution of products to Medtronic. It manufactures transseptal crossing devices and associated accessories, such as integrated transseptal dilators and needles, fixed-curve or steerable introducers, and steerable sheaths (Products). These Products are used to access the left side, or left atrium, of the cardiac anatomy and are used in a range of medical applications, including in electrophysiology and structural heart procedures. The technology supports physicians during a critical component of an ablation or structural heart procedure. The transseptal crossing devices that it manufactures for Medtronic include versions that are length-, diameter- and tip-matched and designed to lock into the hub of sheaths used in many left-heart procedures.
ACUTUS MEDICAL, INC. 
